• 1
    Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429455.
  • 2
    Wu JC. Mycophenolate mofetil. Molecular mechanism of action. Perspectives Drug Discovery Design 1994; 2: 185.
  • 3
    Morris RE, Hoyt EG, Eugui EM, Allison AC. Prolongation of rat heart allograft survival by RS-61443. Surg Forum 1989; 40: 337.
  • 4
    Hao L, Lafferty KJ, Allison AC, Eugui EM. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990; 22: 876879.
  • 5
    Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 16591662.
  • 6
    Platz KP, Bechstein WO, Eckhoff DE, Suzuki Y, Sollinger HW. RS-61443 reverses acute allograft rejection in dogs. Surgery 1991; 110: 736740.
  • 7
    Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443 – a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428432.
  • 8
    Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients. a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups [published erratum appears in Transplantation 1997, February 27; 63 (4): 618]. Transplantation 1997; 63: 3947.
  • 9
    Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998; 31: 329333.
  • 10
    Van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261266.
  • 11
    Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem 1998; 44: 381387.
  • 12
    Meiser BM, Pfeiffer M, Schmidt D et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143149.
  • 13
    Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem 1998; 44: 428432.
  • 14
    Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 1992; 23: 428448.
  • 15
    Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000; 12: 557562.
  • 16
    Gummert JF, Barten MJ, Sherwood SW, Van Gelder T, Morris RE. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther 1999; 291: 11001112.
  • 17
    Gummert JF, Barten MJ, Van Gelder T, Billingham ME, Morris RE. Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation 2000; 70: 10381049.
  • 18
    Barten MJ, Gummert JF, Van Gelder T, Shorthouse R, Morris RE. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Meth Methods 2001; 253: 95112.
  • 19
    Barten MJ, Van Gelder T, Gummert JF, Shorthouse R, Morris RE. Novel assays of multiple lymphocyte functions in whole blood measure new mechanism of action of mycophenolate mofetil in vivo. Transpl Immunol 2002; 10: 1.
  • 20
    Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
  • 21
    Shifrine M, Taylor NJ, Rosenblatt LS, Wilson FD. Comparison of whole blood and purified canine lymphocytes in a lymphocyte-stimulation microassay. Am J Vet Res 1978; 39: 687.
  • 22
    Thompson SC, Bowen KM, Burton RC. Sequential monitoring of peripheral blood lymphocyte subsets in rats. Cytometry 1986; 7: 184.
  • 23
    Sugioka N, Koyama H, Ohta T, Kishimoto H, Yasumura T, Takada K. Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. J Pharm Sci 1996; 85: 335338.
  • 24
    Shaw LM, Nowak I. Mycophenolic acid. measurement and relationship to pharmacologic effects. Ther Drug Monit 1995; 17: 685689.
  • 25
    Gummert JF, Christians U, Barten M, Silva HT, Morris RE. A high-performance liquid chromatographic assay with a simple extraction procedure for sensitive quantification of mycophenolic acid in rat and human plasma. J Chromatogr B Biomed Appl 1999; 721: 321.
  • 26
    Langman LJ, Nakakura H, Thliveris JA, Le GD, Yatscoff RW. Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model. Ther Drug Monit 1997; 19: 146152.DOI: 10.1097/00007691-199704000-00005
  • 27
    Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710720.
  • 28
    Laliberte J, Yee A, Xiong Y, Mitchell BS. Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood 1998; 91: 28962904.
  • 29
    Qiu Y, Fairbanks LD, Ruckermann K et al. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes. Transplantation 2000; 69: 890897.
  • 30
    Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270: 2968229689.
  • 31
    Ruckemann K, Fairbanks LD, Carrey EA et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273: 2168221691.
  • 32
    Catapano CV, Dayton JS, Mitchell BS, Fernandes DJ. GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol Pharmacol 1995; 47: 948955.
  • 33
    Mustelin T. GTP dependence of the transduction of mitogenic signals through the T3 complex in T lymphocytes indicates the involvement of a G-protein. FEBS Lett 1987; 213: 199.
  • 34
    Lub M, Van Kooyk Y, Figdor CG. Ins and outs of LFA-1. Immunol Today 1995; 16: 479483.
  • 35
    Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 7784.
  • 36
    Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996; 24: 5967.
  • 37
    Hayes GR, Williams A, Costello CE, Enns CA, Lucas JJ. The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide. Glycobiology 1995; 5: 227232.
  • 38
    Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425434.
  • 39
    Jepson S, Brogan IJ, Stoddart RW, Hutchinson IV. Mycophenolic acid does not inhibit protein glycosylation in T lymphocytes. Transpl Immunol 2000; 8: 169175.
  • 40
    Forrest TL, Ware RE, Howard T, Jaffee BD, Denning SM. Novel mechanisms of brequinar sodium immunosuppression on T cell activation. Transplantation 1994; 58: 920926.
  • 41
    Ohh M, Smith CA, Carpenito C, Takei F. Regulation of intercellular adhesion molecule-1 gene expression involves multiple mRNA stabilization mechanisms: effects of interferon- gamma and phorbol myristate acetate. Blood 1994; 84: 26322639.
  • 42
    Thomson AW, Woo J, Yao GZ, Todo S, Starzl TE, Zeevi A. Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl Immunol 1993; 1: 146150.
  • 43
    Haug CE, Colvin RB, Delmonico FL et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993; 55: 766772.
  • 44
    Hourmant M, Bedrossian J, Durand D et al. Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Transplant Proc 1995; 27: 864.
  • 45
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 Int Study Group. Lancet 1997; 350: 11931198.
  • 46
    Van Gelder T, Zietse R, Mulder AH et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995; 60: 248252.
  • 47
    Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161165.
  • 48
    Klupp J, Van Gelder T, Regieli J, Shorthouse R, Kavanau K, Morris RE. Development of a novel pharmacodynamic assay in non-human primates. Transplantation 2000; 69 (Suppl.): S125.
  • 49
    Van Gelder T, Klupp J, Kavanau K, Morris RE. Novel mechanisms of action of mycophenolic acid (MPA): Inhibition of expression of CD28 and CD154 co-stimulatory molecules and induction of apoptosis in vivo in humans after treatment with mycophenolate mofetil (MMF). Transplantation 2000; Suppl. 69: S393.